Integrated analysis of FHIT gene alterations in cancer

References

• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi: 10.1016/j.cell.2011.02.013
   PubMed Web of Science ®Google Scholar
• Glover TW, Wilson TE, Arlt MF. Fragile sites in cancer: more than meets the eye. Nat Rev Cancer. 2017;17(8):489–501. doi: 10.1038/nrc.2017.52
   PubMed Web of Science ®Google Scholar
• Pekarsky Y, Garrison PN, Palamarchuk A, et al. Fhit is a physiological target of the protein kinase Src. Proc Natl Acad Sci. 2004;101(11):3775–3779. doi: 10.1073/pnas.0400481101
   PubMed Web of Science ®Google Scholar
• Nishizaki M, Sasaki J-I, Fang B, et al. Synergistic tumor suppression by coexpression of FHIT and p53 coincides with FHIT-Mediated MDM2 inactivation and p53 stabilization in human non-small cell lung cancer cells. Cancer Res. 2004;64(16):5745–5752. doi: 10.1158/0008-5472.CAN-04-0195
   PubMed Web of Science ®Google Scholar
• Rimessi A, Marchi S, Fotino C, et al. Intramitochondrial calcium regulation by the FHIT gene product sensitizes to apoptosis. Proc Natl Acad Sci. 2009;106(31):12753–12758. doi: 10.1073/pnas.0906484106
   PubMed Web of Science ®Google Scholar
• Brenner CH. Hint, Fhit, and GalT: function, structure, evolution, and mechanism of three branches of the histidine triad superfamily of nucleotide hydrolases and transferases. Biochemistry. 2002;41(29):9003–9014. doi: 10.1021/bi025942q
   PubMed Web of Science ®Google Scholar
• Pace HC, Garrison PN, Robinson AK, et al. Genetic, biochemical, and crystallographic characterization of fhit–substrate complexes as the active signaling form of fhit. Proc Natl Acad Sci. 1998;95(10):5484–5489. doi: 10.1073/pnas.95.10.5484
   PubMed Web of Science ®Google Scholar
• Lima CD, Klein MG, Hendrickson WA. Structure-based analysis of catalysis and substrate definition in the HIT protein family. Science. 1997;278(5336):286–290. doi: 10.1126/science.278.5336.286
   PubMed Web of Science ®Google Scholar
• Barnes LD, Fhit, a Putative Tumor Suppressor in Humans, Is a Dinucleoside 5',5' ''-P 1,P 3 -Triphosphate Hydrolase. Biochemistry. 1996;35(36):11529–11535. doi: 10.1021/bi961415t
   PubMed Web of Science ®Google Scholar
• Draganescu A, Hodawadekar SC, Gee KR, et al. Fhit-nucleotide specificity probed with novel fluorescent and fluorogenic substrates. J Biol Chem. 2000;275(7):4555–4560. doi: 10.1074/jbc.275.7.4555
   PubMed Web of Science ®Google Scholar
• Brenner C, Pace HC, Garrison PN, et al. Purification and crystallization of complexes modeling the active state of the fragile histidine triad protein. Protein Eng Des Sel. 1997;10(12):1461–1463. doi: 10.1093/protein/10.12.1461
   Google Scholar
• Guranowski A, Wojdyła AM, Pietrowska-Borek M, et al. Fhit proteins can also recognize substrates other than dinucleoside polyphosphates. FEBS Lett. 2008;582(20):3152–3158. doi: 10.1016/j.febslet.2008.07.060
   PubMed Web of Science ®Google Scholar
• Wojdyła-Mamoń AM, Guranowski A. Adenylylsulfate–ammonia adenylyltransferase activity is another inherent property of fhit proteins. Biosci Rep. 2015;35(4):e00235. doi: 10.1042/BSR20150135
   PubMedGoogle Scholar
• Zamecnik PG, Stephenson ML, Janeway CM, et al. Enzymatic synthesis of diadenosine tetraphosphate and diadenosine triphosphate with a purified lysyl-sRNA synthetase. Biochem Biophys Res Commun. 1966;24(1):91–97. doi: 10.1016/0006-291X(66)90415-3
   PubMed Web of Science ®Google Scholar
• Goerlich O, Foeckler R, Holler E. Mechanism of synthesis of Adenosine(5’)tetraphospho(5’)adenosine (AppppA) by Aminoacyl-tRNA Synthetases. Eur J Biochem. 1982;126(1):135–142. doi: 10.1111/j.1432-1033.1982.tb06757.x
   PubMedGoogle Scholar
• Brevet A, Chen J, Lévêque F, et al. In vivo synthesis of adenylylated bis(5’-nucleosidyl) tetraphosphates (Ap4N) by Escherichia coli aminoacyl-tRNA synthetases. Proc Natl Acad Sci. 1989;86(21):8275–8279. doi: 10.1073/pnas.86.21.8275
   PubMed Web of Science ®Google Scholar
• Merkulova T, Kovaleva G, Kisselev LP. P1 , P3 -bis(5’-adenosyl)triphosphate (ap 3 A) as a substrate and a product of mammalian tryptophanyl-tRNA synthetase. FEBS Lett. 1994;350(2–3):287–290. doi: 10.1016/0014-5793(94)00764-0
   PubMed Web of Science ®Google Scholar
• Flores NA, Stavrou BM, Sheridan DJ. The effects of diadenosine polyphosphates on the cardiovascular system. Cardiovasc Res. 1999;42(1):15–26. doi: 10.1016/S0008-6363(99)00004-8
   PubMed Web of Science ®Google Scholar
• Verspohl EJ, Johannwille B. Diadenosine polyphosphates in insulin-secreting cells: interaction with specific receptors and degradation. Diabetes. 1998;47(11):1727–1734. doi: 10.2337/diabetes.47.11.1727
   PubMed Web of Science ®Google Scholar
• Luthje J, Ogilvie A. Catabolism of Ap3A and Ap4A in human plasma. Purification and characterization of a glycoprotein complex with 5’-nucleotide phosphodiesterase activity. Eur J Biochem. 1985;149(1):119–127. doi: 10.1111/j.1432-1033.1985.tb08901.x
   PubMedGoogle Scholar
• Rubino A, Burnstock G. Possible role of diadenosine polyphosphates as modulators of cardiac sensory-motor neurotransmission in guinea-pigs. J Physiol. 1996;495(2):515–523. doi: 10.1113/jphysiol.1996.sp021611
   PubMed Web of Science ®Google Scholar
• Vartanian A, Alexandrov I, Prudowski I, et al. Ap 4 A induces apoptosis in human cultured cells. FEBS Lett. 1999;456(1):175–180. doi: 10.1016/S0014-5793(99)00956-4
   PubMed Web of Science ®Google Scholar
• Fisher DI, McLennan AG. Correlation of intracellular diadenosine triphosphate (Ap3A) with apoptosis in fhit-positive HEK293 cells. Cancer Lett. 2008;259(2):186–191. doi: 10.1016/j.canlet.2007.10.007
   PubMed Web of Science ®Google Scholar
• Siprashvili Z, Sozzi G, Barnes LD, et al. Replacement of fhit in cancer cells suppresses tumorigenicity. Proc Natl Acad Sci. 1997;94(25):13771–13776. doi: 10.1073/pnas.94.25.13771
   PubMed Web of Science ®Google Scholar
• Roz L, Gramegna M, Ishii H, et al. Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in lung and cervical cancer cell lines. Proc Natl Acad Sci. 2002;99(6):3615–3620. doi: 10.1073/pnas.062030799
   PubMed Web of Science ®Google Scholar
• Trapasso F, Krakowiak A, Cesari R, et al. Designed FHIT alleles establish that fhit-induced apoptosis in cancer cells is limited by substrate binding. Proc Natl Acad Sci. 2003;100(4):1592–1597. doi: 10.1073/pnas.0437915100
   PubMed Web of Science ®Google Scholar
• Herzog D, Jansen J, Mißun M, et al. Chemical proteomics of the tumor suppressor fhit covalently bound to the cofactor Ap3 a elucidates its inhibitory action on translation. J Am Chem Soc. 2022;144(19):8613–8623. doi: 10.1021/jacs.2c00815
   PubMed Web of Science ®Google Scholar
• Lee PC, Bochner BR, Ames BN. AppppA, heat-shock stress, and cell oxidation. Proc Natl Acad Sci. 1983;80(24):7496–7500. doi: 10.1073/pnas.80.24.7496
   PubMed Web of Science ®Google Scholar
• Baker JC, Jacobson MK. Alteration of adenyl dinucleotide metabolism by environmental stress. Proc Natl Acad Sci. 1986;83(8):2350–2352. doi: 10.1073/pnas.83.8.2350
   PubMed Web of Science ®Google Scholar
• Krüger L, Albrecht CJ, Schammann HK, et al. Chemical proteomic profiling reveals protein interactors of the alarmones diadenosine triphosphate and tetraphosphate. Nat Commun. 2021;12(1):5808. doi: 10.1038/s41467-021-26075-4
   PubMed Web of Science ®Google Scholar
• Albrecht CJ, Stumpf FM, Krüger L, et al. Chemical proteomics reveals interactors of the alarmone diadenosine triphosphate in the cancer cell line H1299†. J Pept Sci. 2023;29(3). doi: 10.1002/psc.3458
   PubMed Web of Science ®Google Scholar
• McLennan AG. Dinucleoside polyphosphates—friend or foe? Pharmacol Ther. 2000;87(2–3):73–89. doi: 10.1016/S0163-7258(00)00041-3
   PubMed Web of Science ®Google Scholar
• Ohta M, Inoue, H., Cotticelli, M. G.,The FHIT gene, spanning the chromosome 3p14.2 fragile site and Renal Carcinoma–associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell. 1996;84(4):587–597. doi: 10.1016/S0092-8674(00)81034-X
   PubMed Web of Science ®Google Scholar
• Sozzi G, Veronese ML, Negrini M, et al. The FHIT gene at 3p14.2 is abnormal in lung cancer. Cell. 1996;85(1):17–26. doi: 10.1016/S0092-8674(00)81078-8
   PubMed Web of Science ®Google Scholar
• Sozzi G, Alder, H., Tornielli, S,Aberrant FHIT transcripts in Merkel cell carcinoma. Cancer Res. 1996;56(11):2472–2474.
   PubMed Web of Science ®Google Scholar
• Negrini M, Monaco, C, Vorechovsky, I. The FHIT gene at 3p14.2 is abnormal in breast carcinomas. Cancer Res. 1996;56(14):3173–3179.
   PubMed Web of Science ®Google Scholar
• Virgilio L, Shuster M, Gollin SM, et al. FHIT gene alterations in head and neck squamous cell carcinomas. Proc Natl Acad Sci. 1996;93(18):9770–9775. doi: 10.1073/pnas.93.18.9770
   PubMed Web of Science ®Google Scholar
• Thiagalingam S, Lisitsyn, NA, Hamaguchi, M. Evaluation of the FHIT gene in colorectal cancers. Cancer Res. 1996;56(13):2936–2939.
   PubMed Web of Science ®Google Scholar
• Shridhar R, Shridhar V, Wang X. Frequent breakpoints in the 3p14.2 fragile site, FRA3B, in pancreatic tumors. Cancer Res. 1996;56(19):4347–4350.
   PubMed Web of Science ®Google Scholar
• Man S, Ellis IO, Sibbering M, et al. High levels of allele loss at the FHIT and ATM genes in non-comedo ductal carcinoma in situ and grade I tubular invasive breast cancers. Cancer Res. 1996;56(23):5484–5489.
   PubMed Web of Science ®Google Scholar
• Panagopoulos I, Pandis, N, Thelin, S. The FHIT and PTPRG genes are deleted in benign proliferative breast disease associated with familial breast cancer and cytogenetic rearrangements of chromosome band 3p14. Cancer Res. 1996;56(21):4871–4875.
   PubMed Web of Science ®Google Scholar
• Mao L, Fan YH, Lotan R, et al. Frequent abnormalities of FHIT, a candidate tumor suppressor gene, in head and neck cancer cell lines. Cancer Res. 1996;56(22):5128–5131.
   PubMed Web of Science ®Google Scholar
• Bignell GR, Greenman CD, Davies H, et al. Signatures of mutation and selection in the cancer genome. Nature. 2010;463(7283):893–898. doi: 10.1038/nature08768
   PubMed Web of Science ®Google Scholar
• Futreal PA, Coin L, Marshall M, et al. A census of human cancer genes. Nat Rev Cancer. 2004;4(3):177–183. doi: 10.1038/nrc1299
   PubMed Web of Science ®Google Scholar
• Fong LYY, Fidanza V, Zanesi N. Muir–Torre-like syndrome in Fhit-deficient mice. Proc Natl Acad Sci. 2000;97(9):4742–4747. doi: 10.1073/pnas.080063497
   PubMed Web of Science ®Google Scholar
• Zanesi N, Fidanza V, Fong LY, et al. The tumor spectrum in FHIT-deficient mice. Proc Natl Acad Sci. 2001;98(18):10250–10255. doi: 10.1073/pnas.191345898
   PubMed Web of Science ®Google Scholar
• Fujishita T, Doi Y, Sonoshita M, et al. Development of spontaneous tumours and intestinal lesions in fhit gene knockout mice. Br J Cancer. 2004;91(8):1571–1574. doi: 10.1038/sj.bjc.6602182
   PubMed Web of Science ®Google Scholar
• Park SH, Bennett-Baker, P., Ahmed, S., Locus-specific transcription silencing at the FHIT gene suppresses replication stress-induced copy number variant formation and associated replication delay. Nucleic Acids Res. 2021;49(13):7507–7524. doi: 10.1093/nar/gkab559
   PubMed Web of Science ®Google Scholar
• Weinstein JN, Collisson EA, Mills GB, et al. The cancer genome atlas pan-cancer analysis project. Nat Genet. 2013;45(10):1113–1120. doi: 10.1038/ng.2764
   PubMed Web of Science ®Google Scholar
• Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–404. doi: 10.1158/2159-8290.CD-12-0095
   PubMed Web of Science ®Google Scholar
• Tate JG, Bamford S, Jubb HC, et al. COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res. 2019;47(D1):D941–D947. doi: 10.1093/nar/gky1015
   PubMed Web of Science ®Google Scholar
• Klonowska K, Czubak K, Wojciechowska M, et al. Oncogenomic portals for the visualization and analysis of genome-wide cancer data. Oncotarget. 2016;7(1):176–192. doi: 10.18632/oncotarget.6128
   PubMed Web of Science ®Google Scholar
• Zack TI, Schumacher SE, Carter SL, et al. Pan-cancer patterns of somatic copy number alteration. Nat Genet. 2013;45(10):1134–1140. doi: 10.1038/ng.2760
   PubMed Web of Science ®Google Scholar
• Martínez-Jiménez F, Muiños F, Sentís I, et al. A compendium of mutational cancer driver genes. Nat Rev Cancer. 2020;20(10):555–572. doi: 10.1038/s41568-020-0290-x
   PubMed Web of Science ®Google Scholar
• Beroukhim R, Getz G, Nghiemphu L, et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci. 2007;104(50):20007–20012. doi: 10.1073/pnas.0710052104
   PubMed Web of Science ®Google Scholar
• Durkin SG, Glover TW. Chromosome fragile sites. Ann Rev Genet. 2007;41(1):169–192. doi: 10.1146/annurev.genet.41.042007.165900
   PubMedGoogle Scholar
• Tsantoulis PK, Kotsinas A, Sfikakis PP, et al. Oncogene-induced replication stress preferentially targets common fragile sites in preneoplastic lesions. A genome-wide study. Oncogene. 2008;27(23):3256–3264. doi: 10.1038/sj.onc.1210989
   PubMed Web of Science ®Google Scholar
• Marsit CJ. Loss of heterozygosity of chromosome 3p21 is associated with mutant TP53 and Better Patient Survival in non–small-Cell lung cancer. Cancer Res. 2004;64(23):8702–8707. doi: 10.1158/0008-5472.CAN-04-2558
   PubMed Web of Science ®Google Scholar
• Sha D, Jin Z, Budczies J, et al. Tumor mutational burden as a predictive biomarker in solid tumors. Cancer Discov. 2020;10(12):1808–1825. doi: 10.1158/2159-8290.CD-20-0522
   PubMed Web of Science ®Google Scholar
• Vilar E, Gruber SB. Microsatellite instability in colorectal cancer—the stable evidence. Nat Rev Clin Oncol. 2010;7(3):153–162. doi: 10.1038/nrclinonc.2009.237
   PubMed Web of Science ®Google Scholar
• Taylor AM, Shih J, Ha G, et al. Genomic and functional approaches to understanding cancer aneuploidy. Cancer Cell. 2018;33(4):676–689.e3. doi: 10.1016/j.ccell.2018.03.007
   PubMed Web of Science ®Google Scholar
• He D, Zhang Y-W, Zhang N-N, et al. Aberrant gene promoter methylation of p16, FHIT, CRBP1, WWOX, and DLC-1 in Epstein–barr virus-associated gastric carcinomas. Med Oncol. 2015;32(4):92. doi: 10.1007/s12032-015-0525-y
   PubMed Web of Science ®Google Scholar
• Inokawa Y, Hayashi M, Begum S, et al. High-risk HPV infection-associated hypermethylated genes in oropharyngeal squamous cell carcinomas. BMC Cancer. 2022;22(1):1146. doi: 10.1186/s12885-022-10227-w
   PubMed Web of Science ®Google Scholar
• Ki K-D, Lee S-K, Tong S-Y, et al. Role of 5’-CpG island hypermethylation of the FHIT gene in cervical carcinoma. J Gynecol Oncol. 2008;19(2):117. doi: 10.3802/jgo.2008.19.2.117
   PubMedGoogle Scholar
• Yang Y, Takeuchi S, Hofmann WK, et al. Aberrant methylation in promoter-associated CpG islands of multiple genes in acute lymphoblastic leukemia. Leuk Res. 2006;30(1):98–102. doi: 10.1016/j.leukres.2005.06.002
   PubMed Web of Science ®Google Scholar
• Kvasha S, Gordiyuk V, Kondratov A, et al. Hypermethylation of the 5’CpG island of the FHIT gene in clear cell renal carcinomas. Cancer Lett. 2008;265(2):250–257. doi: 10.1016/j.canlet.2008.02.036
   PubMed Web of Science ®Google Scholar
• Maruyama R, Toyooka S, Toyooka KO., Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res. 2001;61(24):8659–8663.
   PubMed Web of Science ®Google Scholar
• Yang Q, Nakamura M, Nakamura Y. Two-hit inactivation of FHIT by loss of heterozygosity and hypermethylation in breast cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2002;8:2890–2893.
   PubMed Web of Science ®Google Scholar
• Kim JS, Kim JW, Han J, et al. Cohypermethylation of p16 and FHIT promoters as a prognostic factor of recurrence in surgically resected stage I non–small cell lung cancer. Cancer Res. 2006;66(8):4049–4054. doi: 10.1158/0008-5472.CAN-05-3813
   PubMed Web of Science ®Google Scholar
• Wali A, Srinivasan R, Shabnam MS, et al. Loss of fragile histidine triad gene expression in advanced lung cancer is consequent to allelic loss at 3p14 locus and promoter methylation. Mol Cancer Res. 2006;4(2):93–99. doi: 10.1158/1541-7786.MCR-05-0070
   PubMed Web of Science ®Google Scholar
• Li Y, Ge D, Lu C. The SMART app: an interactive web application for comprehensive DNA methylation analysis and visualization. Epigenet Chromatin. 2019;12(1):71. doi: 10.1186/s13072-019-0316-3
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer genome landscapes. Science. 2013;339(6127):1546–1558. doi: 10.1126/science.1235122
   PubMed Web of Science ®Google Scholar
• Bailey MH, Tokheim C, Porta-Pardo E, et al. Comprehensive characterization of cancer Driver genes and mutations. Cell. 2018;173(2):371–385.e18. doi: 10.1016/j.cell.2018.02.060
   PubMed Web of Science ®Google Scholar
• Miuma S, Saldivar JC, Karras JR, et al. Fhit deficiency-induced global genome instability promotes mutation and clonal expansion. PLoS One. 2013;8(11):e80730. doi: 10.1371/journal.pone.0080730
   PubMed Web of Science ®Google Scholar
• Paisie CA, Schrock, M. S., Karras, J. R., Exome‐wide single‐base substitutions in tissues and derived cell lines of the constitutive fhit knockout mouse. Cancer Sci. 2016;107(4):528–535. doi: 10.1111/cas.12887
   PubMed Web of Science ®Google Scholar
• Volinia S, Druck T, Paisie CA, et al. The ubiquitous ‘cancer mutational signature’ 5 occurs specifically in cancers with deleted FHIT alleles. Oncotarget. 2017;8(60):102199–102211. doi: 10.18632/oncotarget.22321
   PubMedGoogle Scholar
• Saldivar JC, Miuma S, Bene J, et al. Initiation of genome instability and preneoplastic processes through loss of fhit expression. PLoS Genet. 2012;8(11):e1003077. doi: 10.1371/journal.pgen.1003077
   PubMed Web of Science ®Google Scholar
• Huiping C, Kristjansdottir S, Bergthorsson JT, et al. High frequency of LOH, MSI and abnormal expression of FHIT in gastric cancer. Eur J Cancer. 2002;38(5):728–735. doi: 10.1016/S0959-8049(01)00432-4
   PubMed Web of Science ®Google Scholar
• Andachi H, Yashima K, Koda M, et al. Reduced fhit expression is associated with mismatch repair deficiency in human advanced colorectal carcinoma. Br J Cancer. 2002;87(4):441–445. doi: 10.1038/sj.bjc.6600501
   PubMed Web of Science ®Google Scholar
• Sarli L, Bottarelli L, Azzoni C, et al. Abnormal fhit protein expression and high frequency of microsatellite instability in sporadic colorectal cancer. Eur J Cancer. 2004;40(10):1581–1588. doi: 10.1016/j.ejca.2004.02.021
   PubMed Web of Science ®Google Scholar
• Vernole P, Muzi A, Volpi A, et al. Common fragile sites in colon cancer cell lines: role of mismatch repair, RAD51 and poly(ADP-ribose) polymerase-1. Mutat Res Mol Mech Mutagen. 2011;712(1–2):40–48. doi: 10.1016/j.mrfmmm.2011.04.006
   PubMed Web of Science ®Google Scholar
• Jahid S, Sun J, Gelincik O, et al. Inhibition of colorectal cancer genomic copy number alterations and chromosomal fragile site tumor suppressor FHIT and WWOX deletions by DNA mismatch repair. Oncotarget. 2017;8(42):71574–71586. doi: 10.18632/oncotarget.17776
   PubMedGoogle Scholar
• Bhandari V, Hoey C, Liu LY, et al. Molecular landmarks of tumor hypoxia across cancer types. Nat Genet. 2019;51(2):308–318. doi: 10.1038/s41588-018-0318-2
   PubMed Web of Science ®Google Scholar
• Da Silva J, Jouida A, Ancel J. FHIT low / pHER2 high signature in non-small cell lung cancer is predictive of anti-HER2 molecule efficacy. J Pathol. 2020;251(2):187–199. doi: 10.1002/path.5439
   PubMed Web of Science ®Google Scholar
• Bianchi F, Magnifico A, Olgiati C, et al. FHIT-proteasome degradation caused by mitogenic stimulation of the EGF receptor family in cancer cells. Proc Natl Acad Sci. 2006;103(50):18981–18986. doi: 10.1073/pnas.0605821103
   PubMed Web of Science ®Google Scholar